Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term romiplostim in pediatric immune thrombocytopenic purpura (ITP)
2009-016203-32Phase 3Completed
- Sponsor
- Amgen
- Start
- Oct 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of romiplostim in immune thrombocytopenia (ITP), sponsored by Amgen. Primary endpoints: Safety (adverse events and laboratory changes) and Immunogenicity (antibody formation). Started Oct 2009; status: completed.
02
Drugs
romiplostim
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on 2009-016203-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016203-32.